3-bromo-6-hydroxy-5,6-dihydropyrrolo[3,4-b]pyridin-7-one | 1431468-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 3-bromo-6-hydroxy-5,6-dihydropyrrolo[3,4-b]pyridin-7-one
• 英文别名: 3-Bromo-6-hydroxy-5,6-dihydro-pyrrolo[3,4-b]pyridin-7-one；3-bromo-6-hydroxy-5H-pyrrolo[3,4-b]pyridin-7-one
• CAS: 1431468-79-9
• 化学式: C₇H₅BrN₂O₂
• 分子量: 229.033
• InChiKey: AKHFMUPVKUALTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴-3-甲基-2-吡啶甲酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 sodium ethanolate 、 potassium carbonate 作用下， 以 甲醇 、 四氯化碳 、 乙腈 、 三氟乙酸 为溶剂， 反应 45.08h， 生成 3-bromo-6-hydroxy-5,6-dihydropyrrolo[3,4-b]pyridin-7-one
  参考文献：
  名称：

  Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

  摘要：

  本发明涉及具有通式II的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、前药、互变异构体、消旋体、对映体或二对映体或其混合物的形式存在，用于治疗、改善或预防病毒性疾病。此外，还披露了特定的联合疗法。

  公开号：

  US20130102601A1

文献信息

• Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102601A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有通式II的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、前药、互变异构体、消旋体、对映体或二对映体或其混合物的形式存在，用于治疗、改善或预防病毒性疾病。此外，还披露了特定的联合疗法。
• PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2794616A1

  公开（公告）日：2014-10-29
• Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20160376286A1

  公开（公告）日：2016-12-29

  The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
• [EN] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4-ONE ET LEUR UTILISATION DANS LE TRAITEMENT, L'AMÉLIORATION OU LA PRÉVENTION D'UNE MALADIE VIRALE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013057253A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, Formula (II) which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
• Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：F. HOFFMANN-LA ROCHE LTD

  公开号：US20130102600A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及一种具有通式I的化合物，可选地以药物可接受的盐、溶剂化物、多晶型、前药、互变异构体、外消旋体、对映体、非对映体或其混合物的形式，该化合物在治疗、改善或预防病毒性疾病方面有用。此外，还公开了特定的组合疗法。